Swiss pharma giant Novartis (NOVN: VX) is consolidating its commitment to radioligand therapies with the establishment of a second production site in China.
The $85 million facility, which will be built in the Zhejiang province, is expected to become operational by 2026.
Novartis already has a radiopharmaceutical manufacturing facility in the Changping district, which has a maximum production capacity of 3 billion tablets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze